-
2024-512186-14-00
6
2020-08-24
Fluid overload/fluid accumulation
-
2023-507885-21-00
4
2020-08-18
Chronic Inflammatory Demyelinating Polyneuropathy
-
2022-501456-28-00
5
2020-07-20
atypical teratoid/rhabdoid tumours (ATRT)
-
2022-501050-11-01
10
2020-07-13
Acute Lymphoblastic Leukaemia
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2024-517854-91-00
5
2019-08-05
Metastatic or high-risk recurrent prostate cancer managed with androge
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2024-518057-41-00
6
2019-02-22
Unexplained cardiac arrest patients after thorough investigations (Idi
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2024-516585-11-00
4
2018-06-12
Advanced melanoma
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2023-506027-29-00
5
2014-10-01
Children, adolescents and adults with newly diagnosed diffuse intrinsi
-
2024-515626-92-00
4
2013-10-18
recurrent/progressive medulloblastoma, ependymoma and atypical teratoi
-
2025-522598-12-00
10
2025-12-17
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
-
2025-521249-25-00
7
2025-10-30
MTAP-deleted advanced or metastatic solid tumors
-
2025-521681-10-00
4
2025-10-02
Lung Cancer
-
2024-520031-33-00
4
2025-09-16
Chronic Inducible Urticaria and Chronic Spontaneous Urticaria
-
2024-518339-12-00
4
2025-07-08
Idiopathic Pulmonary Fibrosis
-
2024-512925-95-00
5
2025-05-16
Advanced/Metastatic Breast Cancer
-
2024-519628-25-00
6
2025-04-03
Chronic rrhinosinusitis with nasal polyps
-
2023-510465-10-00
4
2025-03-10
Meningococcal immunization
-
2024-518343-38-00
5
2025-02-12
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C